{"id":"W1538330154","doi":"10.1158/1538-7445.sabcs14-ot3-1-06","title":"Abstract OT3-1-06: A phase 2 single-arm study to evaluate the clinical activity, safety and tolerability of enzalutamide (ENZA) with trastuzumab in patients with advanced human growth factor receptor 2 (HER2)-positive breast cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Tolerability; Medicine; Enzalutamide; Oncology; Internal medicine; Clinical endpoint; Metastatic breast cancer; Cancer; Breast cancer; Clinical trial; Androgen receptor; Adverse effect; Prostate cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00276109,0.002569415,0.003361174,0.0005520499,0.0006100045,0.001561819,0.00147033,0.002251429,0.00762252],"category_scores_gemma":[0.001050679,0.0008507274,0.001789129,0.0007951501,0.001649812,0.001322996,0.000413257,0.004078431,0.001751525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0015021,"about_ca_system_score_gemma":0.003221132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001692651,"about_ca_topic_score_gemma":0.005168604,"domain_scores_codex":[0.9993964,0.0002522582,0.00003214842,0.00009661682,0.00007150869,0.0001510152],"domain_scores_gemma":[0.9990603,0.0001084209,0.0001660586,0.00005619022,0.00005702253,0.0005519465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7953044,0.102359,0.003062163,0.001419334,0.001211914,0.0003094082,0.0002712141,0.001730219,0.03084009,0.0003643956,0.006143244,0.05698472],"study_design_scores_gemma":[0.6601562,0.3323418,0.003280652,0.00003495493,0.0003048739,0.0001836676,0.00003686129,0.0007668085,0.00102367,0.0001834365,0.001656454,0.00003063094],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804026,0.003208423,0.0009795524,0.0006791992,0.0002483111,0.008295701,0.00317522,0.0002763579,0.002734634],"genre_scores_gemma":[0.9722401,0.003192081,0.003381527,0.002561769,0.0003628319,0.008361875,0.004066442,0.0001030329,0.005730341],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00762252,"threshold_uncertainty_score":0.02549982,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1184638961843083,"score_gpt":0.4699036391384115,"score_spread":0.3514397429541033,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}